Study on anti-atherosclerosis mechanism of blood components of Guanxin Qiwei tablets based on HPLC-Q-Exactive-MS/MS and network pharmacology
10.16438/j.0513-4870.2024-0741
- VernacularTitle:基于HPLC-Q-Exactive-MS/MS及网络药理学的冠心七味片入血成分抗动脉粥样硬化机制研究
- Author:
Yuan-hong LIAO
1
;
Jing-kun LU
2
;
Yan NIU
2
;
Jun LI
1
;
Ren BU
1
;
Peng-peng ZHANG
3
;
Yue KANG
3
;
Yue-wu WANG
1
Author Information
1. College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
2. School of Basic Medicine, Inner Mongolia Medical University, Hohhot 010110, China
3. Baotou Traditional Chinese Medicine Co., Ltd., Baotou 014040, China
- Publication Type:Research Article
- Keywords:
Guanxin Qiwei tablet;
network pharmacology;
atherosclerosis;
blood component;
lipid metabolism
- From:
Acta Pharmaceutica Sinica
2025;60(2):449-458
- CountryChina
- Language:Chinese
-
Abstract:
The analysis presented here is based on the blood components of Guanxin Qiwei tablets, the key anti-atherosclerosis pathway of Guanxin Qiwei tablets was screened by network pharmacology, and the anti-atherosclerosis mechanism of Guanxin Qiwei tablets was clarified and verified by cell experiments. HPLC-Q-Exactive-MS/MS technique was used to analyze the components of Guanxin Qiwei tablets into blood, to determine the precise mass charge ratio of the compounds, and to conduct a comprehensive analysis of the components by using secondary mass spectrometry fragments and literature comparison. Finally, a total of 42 components of Guanxin Qiwei tablets into blood were identified. To better understand the interactions, we employed the Swiss Target Prediction database to predict the associated targets. Atherosclerosis (AS) disease targets were searched in disease databases Genecard, OMIM and Disgent, and 181 intersection targets of disease targets and component targets were obtained by Venny 2.1.0 software. Protein interactions were analyzed by String database. The 32 core targets were selected by Cytscape software. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed in DAVID database. It was found that the anti-atherosclerosis pathways of Guanxin Qiwei tablets mainly include lipid metabolism and atherosclerosis and AGE-RAGE signaling pathway in diabetic complications and other signal pathways. The core targets and the core compounds were interlinked, and it was found that cryptotanshinone and tanshinone ⅡA in Guanxin Qiwei tablets were well bound to TNF, PPARγ, AKT1, PTG2 and other targets. The lipid metabolism and atherosclerotic pathway was verified using human hl-7702 hepatocytes. This study preliminarily identified the potential pharmacodynamic components of Guanxin Qiwei tablets in the treatment of AS diseases and predicted their pathways of action, and verified the relationship between regulating lipid metabolism and atherosclerosis of Guanxin Qiwei tablets in vitro, providing a reference for the further study of the pharmacodynamic material basis and mechanism of action of this prescription. This experiment was approved by the Medical Ethics Committee of Inner Mongolia Medical University (No. YKD202401262).
